8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 24, 2026·SEC
Fractyl Health, Inc. Common Stock(GUTS)Earnings, Financials & Key Ratios
GUTS•NASDAQ
$0.78
Price updated Jul 2, 2026
AboutFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$96M-3.1%
- Net Income-$141M-105.2%
- EPS (Diluted)-1.86-14.8%
- ROE-744.17%-207.9%
GUTS Price & Volume
Fractyl Health, Inc. Common Stock (GUTS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Fractyl Health operates as a high-risk, pre-revenue entity heavily dependent on external financing to sustain its Revita system development.
- While the company reported a $9.2 million net income in 2026Q1, this figure appears decoupled from operational reality given the persistent quarterly cash burn exceeding $20 million.
- Investors should monitor the company's ability to reach commercial scale before its $63.2 million cash position is exhausted by ongoing R&D requirements.
Verdict Logic
the company's reliance on external financing is highlighted by a consistent quarterly cash burn that has reduced the total asset base from $163.5 million in 2024Q1 to $99.4 million by 2026Q1.
GUTS Growth Metrics
Fractyl Health, Inc. Common Stock (GUTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5.43%
Return on Capital
10 Years-170.55%
5 Years-91.05%
3 Years-102.95%
Last Year-101.18%
GUTS Recent Earnings
Fractyl Health, Inc. Common Stock (GUTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.06+135.3%
$0.17
Rev
—
—
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.15+178.9%
$0.19
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.35-2.9%
$0.34
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.53-43.2%
$0.37
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.06vs $0.17+135.3% | — |
| Q2 2026 | Mar 24, 2026 | $0.15vs $0.19+178.9% | — |
| Q4 2025 | Nov 12, 2025 | $0.35vs $0.34-2.9% | — |
| Q3 2025 | Aug 12, 2025 | $0.53vs $0.37-43.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Fractyl Health, Inc. Common Stock (GUTS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.78 | $56.49M | -0.42 | -100% | — | -744.17% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $48.76 | $2.97B | -26.64 | — | — | -21.04% | — | |
| $10.18 | $299.1M | -2.03 | -92.81% | -8550.65% | — | — | |
| $5.19 | $20.49M | -3.46 | -31.76% | -7.98% | -15.41% | — | |
| $25.98 | $4.12B | -8.75 | — | — | -52.2% | — |
Compare GUTS vs Peers
Fractyl Health, Inc. Common Stock (GUTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GUTS SEC Filings & Documents
Fractyl Health, Inc. Common Stock (GUTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GUTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GUTS Frequently Asked Questions
Fractyl Health, Inc. Common Stock (GUTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Fractyl Health, Inc. Common Stock growing?
Fractyl Health, Inc. Common Stock (GUTS) saw revenue decline by 100.0% over the past year.
Is GUTS profitable?
Fractyl Health, Inc. Common Stock (GUTS) reported a net loss of $108.0M for fiscal year 2025.
Dividend & Returns
What is GUTS's return on equity?
Fractyl Health, Inc. Common Stock (GUTS) has a return on equity (ROE) of -744.2%. Negative ROE indicates the company is unprofitable.
What is Fractyl Health, Inc. Common Stock's free cash flow?
Fractyl Health, Inc. Common Stock (GUTS) had negative free cash flow of $87.8M in fiscal year 2025, likely due to heavy capital investments.